ERBB2 and breast carcinoma: A Phase II trial of HKI‐272 (neratinib), neratinib and capecitabine, and ado‐trastuzumab emtansine for patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer and brain metastases